000282629 001__ 282629
000282629 005__ 20251212153250.0
000282629 0247_ $$2doi$$a10.1186/s13195-025-01902-8
000282629 0247_ $$2pmid$$apmid:41345718
000282629 0247_ $$2pmc$$apmc:PMC12696915
000282629 037__ $$aDZNE-2025-01365
000282629 041__ $$aEnglish
000282629 082__ $$a610
000282629 1001_ $$0P:(DE-2719)9001238$$aPlaten, Moritz$$b0$$eFirst author$$udzne
000282629 245__ $$aRegional disparities of antidementia drug treatment in Germany: what can we learn for the new generation of Alzheimer's therapies.
000282629 260__ $$aLondon$$bBioMed Central$$c2025
000282629 3367_ $$2DRIVER$$aarticle
000282629 3367_ $$2DataCite$$aOutput Types/Journal article
000282629 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1765549866_25188
000282629 3367_ $$2BibTeX$$aARTICLE
000282629 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282629 3367_ $$00$$2EndNote$$aJournal Article
000282629 520__ $$aCurrent antidementia drugs can temporarily slow cognitive decline in Alzheimer's disease but are underused. Regional and socioeconomic disparities, including limited specialist access in rural or deprived areas, may exacerbate inequities and challenge the rollout of emerging disease-modifying therapies. This study aimed to evaluate associations between regional contextual factors and antidementia drug prescription (AD-Rx) among newly diagnosed people living with Alzheimer's disease (PlwAD) in Germany and to identify spatial clustering of prescribing patterns.This study analyzed anonymized claims data from three statutory health insurers for 53,753 PlwAD who received their first diagnosis between January 2020 and December 2022. Regions, defined by three-digit postal codes (ZIP3, n = 576), were categorized by the German Index of Socioeconomic Deprivation (GISD) quintiles and Degree of Urbanization (urban, suburban, rural). Multilevel logistic regression with random intercepts for ZIP3 was used to assess associations between receiving AD-Rx (dichotomous) and urbanization and deprivation, adjusting for age, sex, the Charlson Comorbidity Index, the long-term care level and the year of diagnosis. Global Moran's I was used to evaluate large-scale spatial clustering, and regional Moran's I was calculated to detect regional hotspots and coldspots.Overall, 64% of PlwAD received at least one AD-Rx. Rural residency was associated with slightly lower odds of receiving AD-Rx compared to urban areas (OR 0.92; 95%CI 0.87-0.98; p = 0.010), whereas deprivation was not. Interaction models demonstrated that an increased deprivation further reduced AD-Rx odds in rural areas (OR per GISD unit = 0.98; 95% CI 0.96-0.99; p = 0.024). Global Moran's I revealed no significant large-scale clustering (I = 0.011; p = 0.613), but regional analysis identified several regional hotspots (high-high clusters) predominantly in moderately deprived urban areas and coldspots (low-low clusters) in highly deprived or rural areas.Alzheimer's patients in rural and high-deprivation regions face limited access to recommended antidementia medications. Targeted interventions, such as teleconsultations, expanding specialist outreach, and collaborative care models in underserved areas, as well as regional dementia networks and national registries, could promote the equitable delivery of current and future Alzheimer's antibody therapies. However, further qualitative and quantitative research is needed to identify the underlying regional causes of these treatment disparities.DRKS00031944.
000282629 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000282629 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000282629 650_7 $$2Other$$aAlzheimer’s disease
000282629 650_7 $$2Other$$aAntidementia drug treatment
000282629 650_7 $$2Other$$aDeprivation
000282629 650_7 $$2Other$$aDisease-modifying treatments, geographical variation, spatial analysis
000282629 650_7 $$2Other$$aHealthcare disparities
000282629 650_7 $$2Other$$aReal-world data
000282629 650_7 $$2Other$$aReal-world evidence
000282629 650_7 $$2Other$$aRural population
000282629 650_7 $$2NLM Chemicals$$aNootropic Agents
000282629 650_2 $$2MeSH$$aHumans
000282629 650_2 $$2MeSH$$aGermany: epidemiology
000282629 650_2 $$2MeSH$$aAlzheimer Disease: drug therapy
000282629 650_2 $$2MeSH$$aAlzheimer Disease: epidemiology
000282629 650_2 $$2MeSH$$aMale
000282629 650_2 $$2MeSH$$aFemale
000282629 650_2 $$2MeSH$$aAged
000282629 650_2 $$2MeSH$$aHealthcare Disparities: statistics & numerical data
000282629 650_2 $$2MeSH$$aAged, 80 and over
000282629 650_2 $$2MeSH$$aRural Population
000282629 650_2 $$2MeSH$$aNootropic Agents: therapeutic use
000282629 650_2 $$2MeSH$$aSocioeconomic Factors
000282629 650_2 $$2MeSH$$aMiddle Aged
000282629 7001_ $$0P:(DE-2719)9003305$$aGläser, Eva$$b1$$udzne
000282629 7001_ $$aDahling, Volker$$b2
000282629 7001_ $$aGesell, Daniela$$b3
000282629 7001_ $$aHauptmann, Michael$$b4
000282629 7001_ $$aHorenkamp-Sonntag, Dirk$$b5
000282629 7001_ $$aKoller, Daniela$$b6
000282629 7001_ $$aKubat, Denise$$b7
000282629 7001_ $$aMarschall, Ursula$$b8
000282629 7001_ $$aRiederer, Cordula$$b9
000282629 7001_ $$aScheibner, Hannah$$b10
000282629 7001_ $$aSchroth, Jennifer$$b11
000282629 7001_ $$aSwart, Enno$$b12
000282629 7001_ $$0P:(DE-2719)2810763$$aMichalowsky, Bernhard$$b13$$eLast author$$udzne
000282629 773__ $$0PERI:(DE-600)2506521-X$$a10.1186/s13195-025-01902-8$$gVol. 17, no. 1, p. 259$$n1$$p259$$tAlzheimer's research & therapy$$v17$$x1758-9193$$y2025
000282629 8564_ $$uhttps://pub.dzne.de/record/282629/files/DZNE-2025-01365.pdf$$yRestricted
000282629 8564_ $$uhttps://pub.dzne.de/record/282629/files/DZNE-2025-01365.pdf?subformat=pdfa$$xpdfa$$yRestricted
000282629 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001238$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000282629 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003305$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000282629 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810763$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b13$$kDZNE
000282629 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000282629 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS RES THER : 2022$$d2024-12-13
000282629 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-13
000282629 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-13
000282629 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-10T15:32:54Z
000282629 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-10T15:32:54Z
000282629 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review$$d2024-04-10T15:32:54Z
000282629 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-13
000282629 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-13
000282629 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-13
000282629 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-13
000282629 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-13
000282629 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-13
000282629 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-13
000282629 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bALZHEIMERS RES THER : 2022$$d2024-12-13
000282629 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-13
000282629 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-13
000282629 9201_ $$0I:(DE-2719)5000067$$kAG Michalowsky$$lPatient-Reported Outcomes and Health Economics Research$$x0
000282629 980__ $$ajournal
000282629 980__ $$aEDITORS
000282629 980__ $$aVDBINPRINT
000282629 980__ $$aI:(DE-2719)5000067
000282629 980__ $$aUNRESTRICTED